Marion Subklewe

62PUBLICATIONS
427CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (62)

|Oct 07, 2026
Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.

|Aug 31, 2026
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma.

|Aug 24, 2026
TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

|Aug 11, 2026
Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and Opportunities.

|Jul 16, 2026
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.

|Apr 14, 2026
Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Enise Ceran, Sonia Jaramillo, Anne Kathrin Merbach

Pageof 11

Frequent Collaborators

22 joint publications

Veit L Bücklein

12 joint publications

Michael D Jain

12 joint publications

Gloria Iacoboni

11 joint publications

Viktoria Blumenberg